Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network

[1]  G. Zamboni,et al.  The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[2]  A. Goldhirsch,et al.  HER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Bartlett,et al.  HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.

[4]  B. Jasani,et al.  Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network Do the results of international clinical trials translate into a similar benefit for patients in South East Wales? , 2011, British Journal of Cancer.

[5]  G. Tortora.  Mechanisms of resistance to HER2 target therapy. , 2011, Journal of the National Cancer Institute. Monographs.

[6]  B. Jasani,et al.  Abstract P3-10-21: Audit of the Accuracy of Immunohistochemical (IHC) Testing of HER2 Status of Breast Cancer in the United Kingdom: An Interim Analysis , 2010 .

[7]  F. Penault-Llorca,et al.  Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer , 2010, British Journal of Cancer.

[8]  E. Perez,et al.  HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[10]  Mitch Dowsett,et al.  Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[12]  S. Paik,et al.  Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31 , 2007 .

[13]  Nandini Dendukuri,et al.  Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis , 2007, Canadian Medical Association Journal.

[14]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[15]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[16]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[17]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[18]  M. Dowsett,et al.  Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres , 2003, The Journal of pathology.

[19]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[20]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.